Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms on their most important mergers, acquisitions and takeover transactions.
LogicBio® Therapeutics to Be Acquired by Alexion, AstraZeneca Rare Disease
- Client News
- October 3, 2022
Paul, Weiss is advising LogicBio® Therapeutics, Inc., a pioneering clinical-stage genomic medicine company, in its sale to Alexion, AstraZeneca Rare Disease (Alexion), an AstraZeneca group focused on rare diseases that was created following AstraZeneca’s 2021 acquisition of Alexion Pharmaceuticals, Inc. The proposed acquisition, announced on October 3, brings LogicBio's unique technology, experienced rare disease R&D team, and expertise in pre-clinical development to support Alexion's growth in genomic medicines.
Under the terms of the agreement, Alexion, through a subsidiary, will initiate a cash tender offer to acquire all outstanding shares of LogicBio for $2.07 per share. The deal expected to close in the fourth quarter of 2022, subject to the tender of at least a majority of the outstanding shares of LogicBio common stock and satisfaction of other closing conditions.
The Paul, Weiss team includes corporate partners Krishna Veeraraghavan, Kyle Seifried, David Huntington and Caith Kushner and counsel Luke Jennings and Jason Tyler; executive compensation partners Jean McLoughlin, Rebecca Coccaro and Lawrence Witdorchic; restructuring partner Robert Britton; intellectual property partner Jonathan Ashtor; litigation partners Geoffrey Chepiga and Joshua Soven, and counsel Peter Jaffe, Steven Herzog and Robert Kravitz; tax partner Brian Krause and counsel Sohail Itani; real estate partner Salvatore Gogliormella; antitrust counsel Yuni Sobel; environmental counsel William O'Brien; and international trade counsel Richard Elliott.